Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma: A Single-centre, Observer-blinded, Randomized Controlled Trial.

NCT03280212 is registered in ClinicalTrials.gov with Unity Health Toronto as lead sponsor.

NCT NCT03280212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03280212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma: A Single-centre, Observer-blinded, Randomized Controlled Trial.
Lead sponsor
Unity Health Toronto
Phase
Phase 3
Overall status
Unknown status
Start date
March 6, 2017
Completion date
March 31, 2018
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic subdural hematoma